Outcomes of patients with differentiated thyroid cancer risk-stratified according to the american thyroid association and latin american thyroid society risk of recurrence classification systems

Thyroid

Volumn 23, Issue 11, 2013, Pages 1401-1407

  Pitoia, Fabián ^a   Bueno, Fernanda ^a   Urciuoli, Carolina ^a   Abelleira, Erika ^a   Cross, Graciela ^a   Tuttle, R Michael ^b  

^a Division of Endocrinology   (Argentina)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ABLATION THERAPY; ADULT; AGED; AMERICAN THYROID ASSOCIATION; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURGERY; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LATIN AMERICAN THYROID SOCIETY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PAPILLARY THYROID CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THYROID CANCER; THYROIDECTOMY; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; AGED; CARCINOMA; DATABASES, FACTUAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LATIN AMERICA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; SOCIETIES, MEDICAL; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; UNITED STATES;

EID: 84887462306     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0011     Document Type: Article

References (24)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 2010 Thyroid. In: AJCC Cancer Staging Manual, 7th ed. Springer, New York, pp 87-96.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648. (Pubitemid 29019586)
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
4. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomnizcze H 2009 Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 53:884-887.
5. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
6. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
7. Vaisman F, Shaha A, Fish S, Tuttle R 2011 Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf ) 2011 Feb 8 [Epub ahead of print]; DOI: 10.1111/j.1365-2265.2011.04002.
8. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F 2011 Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165: 441-446.
9. Vaisman F, Tala H, Grewal R, Tuttle RM 2011 In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 21:1317-1322.
10. Pitoia F, Ward L 2010 Differences between Latin American and American Associations' thyroid cancer guidelines. Thyroid 4:361-362; discussion 362.
11. Rondeau G, Tuttle RM 2011 Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. Semin Nucl Med 41:89-95.
12. Hugo J, Robenshtok E, Grewal R, Larson SM, Tuttle RM Md.2012 Recombinant human TSH-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 22:1007-1015.
13. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM 2012 Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf ) 77:132-138.
14. Randolph G, Duh QY, Heller KS, Livolsi VA, Mandel SJ, Steward D, Tufano RP, Tuttle RM Md 2012 The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. ATA Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. Thyroid 22:1144-1152.
15. Roti E, degli Uberti EC, Bondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and metaanalysis study. Eur J Endocrinol 159:659-673.
16. Mazzaferri EL 2007 Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498-512.
17. Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, Miyauchi A 2012 Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J 59:119-125.
18. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, Pacini F 2011 The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 34:219-223.
19. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111. (Pubitemid 36337763)
20. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488-1492.
21. Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri M 2005 Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest 28:540-546. (Pubitemid 43162888)
22. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M 2008 Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid 18:1049-1053.
23. Valadão MM, Rosário PW, Borges MA, Costa GB, Rezende LL, Padrão EL, Barroso AL, Purisch S 2006 Positive predictive value of detectable stimulated Tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months. Thyroid 16:1145-1149. (Pubitemid 44864489)
24. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402-3407. (Pubitemid 38951911)